Joseph West Email & Phone Number

Biotech advisory firm for Business Development, Operations & Commercial Strategy

Boston, MA, US

Responsible for executing business strategy and fueling growth from external sources via M&A, R&D partnerships, and out-licensing.Working closely with the CEO and members of the leadership team to help define the corporate vision and strategy for long range planning, including corporate development and partnering strategy* Build corporate structure and.

Tübingen, Baden-Württemberg, DE

• Responsible for initiating, leading and executing corporate strategy and spearheading development and growth in multiple key therapeutic areas (Oncology, Vaccines/Infectious Disease [COVID-19] and Molecular.
• Propose and implement improvements in internal operations and governance
• Provide overall direction of portfolio management and resource planning for both internal and external initiatives, ensuring alignment with strategic growth goals
• Encourage, coach and foster success-oriented performance, setting clear expectations and objectives
• Ensure collaboration among senior management on the execution of sensitive and high value initiatives
• Provide insights for improving strategic initiatives, informed decision making

Stamford, CT, US

• Responsible for executing business strategy and fueling growth from external sources via M&A, in-licensing, out-licensing, alliances, and other collaborative arrangements.
• Establish collaborative relationships and maintain close communication with the senior management team and other key internal stakeholders including R&D, legal, regulatory, finance and commercial regarding current.
• Provide strategic direction in evaluating target areas, targets of interest and licensing opportunities
• Negotiate and close global deals that strategically diversify the business and drive growth consistent with overall strategy
• Provide direction to teams in evaluating target areas, targets of interest and licensing opportunities
• Assure appropriate deal structure, terms, financial models and value creation within the framework of applicable strategies and objectives

Washington, DC, US

• Providing clients with transformational commercial planning, infrastructure development, and mission critical business issue identification.
• Partnered with a large venture capital firm, led a multi-disciplinary due diligence team for a company acquisition in home healthcare delivery.
• Provided strategic solutions and transformational management for Prescription Benefit Management organizations and Accountable Care Organizations including business requirements, operational resources and capital.
• Guided commercial direction and led cross-functional teams for two rare disease product launches.
• Developed strategic solutions and tactical implementation of operational tools including CRM, SFA, portals, data warehousing, dashboards and analytics, forecasting, integration with legacy systems, outsourcing versus.
• Led the development of commercial plans, roadmaps, and timelines through hands-on, cross-functional communication across all levels in the organization. This includes products launched in the fields of oncology.

• Led strategic commercial direction (Sales & Marketing), corporate development and strategic partnerships, commercial asset identification, acquisition, and asset out-licensing.
• Achieved successful execution of M&A transaction to MEDA Pharmaceuticals for $200M.
• Directed development of commercialization plans for company’s lead asset - AEROSPAN™ including resourcing and supply chain.
• Managed multiple business initiatives in a start-up environment including sales force design and execution, and sales analytics.

Cumberland, RI, US

• Spearheaded corporate strategic direction for inorganic and organic growth for Onset Dermatologics (Rx), PrecisionMD (physician dispensed therapies), and ProSkin (OTC). Led a team of senior executives, external.
• Consummated multiple major business transactions in North America and Europe, increased revenues by 10%, and strategically positioned the company as an attractive target for M&A, resulting in successful transaction.
• Recommended optimization of internal core competencies and resources, increasing EBITDA by 5%.
• Identified, led all M&A diligence activities including planning, funding, sourcing, integration, asset acquisition and asset out-licensing.

Marlborough, MA, US

• Led worldwide business activities for opportunities in central nervous system, respiratory/critical care, and institutional lines of business. Managed a multi-functional team of 10 senior managers, responsible for.
• Executed $600M+ in business transactions in North America, Europe, and Asia in pipeline acquisition, R&D collaborations, and asset out-licensing.
• Orchestrated the culmination of M&A and strategic licensing resulting in successful $2.6B sale of company to Dainippon Sumitomo Pharmaceuticals in Osaka, Japan.
• Led commercial teams in evaluations, research, identification, and recommending therapeutic areas of strategic importance for future investments and growth.
• Developed and led an Alliance Management Program ensuring internal and external objectives alignment, implementation, and governance.

• Managed portfolio planning and commercial analytics for in-line brands and products in development. Developed pre-launch strategies: positioning, messaging, pricing, and advocacy identification. Oversaw staff of 12 and.
• Led product positioning, creation of marketing communication plan, and selling materials for first commercial product, Xopenex, which peaked at $500M in sales and captured a 28% market share.
• Commercial Team Lead establishing Lunesta as a household brand, recognized as a leading product launch in pharmaceutical history, achieving $700M in peak sales.
• Negotiated co-promotion agreements with Medpointe Pharmaceuticals on Astelin and with Ross (a division of Abbott) on Xopenex; Provided input as a Business Development team member.
• Introduced core research function supporting product planning and business development evaluations.
• Established portfolio prioritization process, forecasting center of excellence, and competitive intelligence.